The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Issue 4 (August 2020)

• Record Type: Journal Article
• Authors: Kimchi, Nofar; Bielory, Leonard
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 20:Issue 4(2020:Aug.)
• Publication Date: 2020-08
• Subjects: allergic conjunctivitis -- cannabis -- flavonoids -- ocular allergy -- ophthalmic antihistamines; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000669
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: Ocular allergies affect an estimated 40% of the population, 98% of which are because of allergic conjunctivitis. With the current advent of both repurposed drugs for ocular allergies, as well as novel drugs and methods of administration, there is a need for an updated review of current available medications. A clear characterization of each treatment will ultimately allow treating physicians to restore patients' quality of life and decrease burden of disease. Recent findings: Currently, there are a number of reformulated antihistamines, with cetrizine being the most recent ophthalmic solution available. Nevertheless, there is ongoing research in the field of immunotherapy, steroids, flavonoids, cannabis, and drug-delivery systems. Summary: Although dual-activity agents remain the keystone for treatment, newer drugs and drug-delivery systems offer other novel directions for delivering appropriate relief with minimal adverse effects.